Stephanie S O'Malley Selected Research

Alcoholism (Alcohol Abuse)

1/2022	Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disorders.
1/2022	Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial.
1/2022	Multimodal neuroimaging of metabotropic glutamate 5 receptors and functional connectivity in alcohol use disorder.
11/2021	The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials.
11/2021	Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.
1/2021	Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder.
1/2021	Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants.
1/2021	Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving.
1/2021	Mapping data-driven individualized neurobehavioral phenotypes in heavy alcohol drinkers.
10/2020	Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephanie S O'Malley Research Topics

Disease

58	Alcoholism (Alcohol Abuse) 01/2022 - 02/2002
10	Tobacco Use Disorder (Nicotine Dependence) 01/2020 - 01/2003
8	Weight Gain 05/2019 - 03/2006
4	Lung Neoplasms (Lung Cancer) 09/2021 - 01/2008
4	Substance-Related Disorders (Drug Abuse) 01/2021 - 04/2007
4	Schizophrenia (Dementia Praecox) 01/2021 - 10/2014
4	Alcohol-Related Disorders 01/2020 - 05/2007
4	Cardiovascular Diseases (Cardiovascular Disease) 04/2015 - 06/2008
3	Body Weight (Weight, Body) 05/2013 - 01/2013
2	Pain (Aches) 01/2022 - 03/2013
2	Mental Disorders (Mental Disorder) 01/2021 - 04/2007
2	Obesity 03/2016 - 10/2014
2	Overweight 10/2015 - 10/2014
2	Sleepiness 02/2015 - 06/2003
2	Weight Loss (Weight Reduction) 10/2014 - 03/2006
2	Nausea 07/2009 - 02/2002
2	Paresthesia (Dysesthesia) 06/2008 - 10/2007
2	Anorexia 06/2008 - 10/2007
1	Major Depressive Disorder (Major Depressive Disorders) 01/2021
1	Flushing 01/2020
1	Anxiety Disorders (Anxiety Disorder) 01/2019
1	Multiple Organ Failure (MODS) 01/2019
1	Alcoholic Liver Diseases (Alcoholic Liver Disease) 04/2018
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 11/2017
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2016
1	Vomiting 01/2016
1	Psychotic Disorders (Schizoaffective Disorder) 10/2014
1	Chronic Disease (Chronic Diseases) 03/2013
1	Prehypertension 06/2008
1	Fatty Liver 06/2008
1	Fibrosis (Cirrhosis) 06/2008
1	Feeding and Eating Disorders (Eating Disorder) 04/2007
1	Gambling (Pathological Gambling) 10/2004

Drug/Important Bio-Agent (IBA)

29	Naltrexone (ReVia)FDA LinkGeneric 01/2022 - 02/2002
11	Nicotine FDA Link 01/2019 - 01/2003
8	Varenicline (Chantix)FDA Link 11/2021 - 05/2007
5	Acamprosate (Campral)FDA Link 11/2021 - 06/2003
5	Pharmaceutical PreparationsIBA 01/2021 - 10/2004
5	Narcotic Antagonists (Opioid Antagonists)IBA 12/2019 - 02/2002
4	Opioid Analgesics (Opioids)IBA 01/2022 - 01/2004
4	Dopamine (Intropin)FDA LinkGeneric 01/2018 - 01/2004
4	gamma-Aminobutyric Acid (GABA)IBA 12/2015 - 01/2004
3	Glutamic Acid (Glutamate)FDA Link 01/2022 - 01/2004
3	SmokeIBA 09/2021 - 01/2008
3	3-carboxamido-4-hydroxynaltrexoneIBA 10/2020 - 10/2018
3	EnzymesIBA 01/2020 - 06/2008
3	Topiramate (Topamax)FDA LinkGeneric 01/2019 - 10/2007
3	Indicators and Reagents (Reagents)IBA 01/2019 - 06/2011
3	Menthol FDA Link 01/2018 - 01/2014
2	saracatinibIBA 01/2022 - 01/2021
2	Biological ProductsIBA 01/2022 - 10/2010
2	Olanzapine (Zyprexa)FDA Link 10/2020 - 05/2019
2	Antipsychotic Agents (Antipsychotics)IBA 05/2019 - 10/2014
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2018 - 07/2009
2	Neurotransmitter Agents (Neurotransmitter)IBA 12/2015 - 01/2004
2	AntioxidantsIBA 04/2015 - 08/2014
2	BilirubinIBA 04/2015 - 08/2014
2	Bupropion (Wellbutrin)FDA LinkGeneric 01/2008 - 05/2007
1	Phosphotransferases (Kinase)IBA 01/2022
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2022
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2022
1	ANS-6637IBA 01/2020
1	AcetaldehydeIBA 01/2020
1	Adenosine Diphosphate (ADP)IBA 01/2020
1	AldehydesIBA 01/2020
1	Drug CombinationsIBA 05/2019
1	Ethanol (Ethyl Alcohol)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 12/2018
1	Irritants (Vesicants)IBA 01/2018
1	MecamylamineIBA 01/2018
1	RacloprideIBA 01/2018
1	nalmefene (Revex)FDA Link 01/2017
1	Nociceptin ReceptorIBA 01/2016
1	NociceptinIBA 01/2016
1	TransferasesIBA 01/2016
1	Peptide Receptors (Peptide Receptor)IBA 01/2016
1	LY2940094IBA 01/2016
1	Aminobutyrates (Aminobutyric Acid)IBA 12/2015
1	N-Methylaspartate (NMDA)IBA 02/2015
1	Memantine (Namenda)FDA Link 02/2015
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 02/2015
1	GABA-A Receptors (GABA(A) Receptor)IBA 03/2013
1	SolutionsIBA 01/2013
1	Opiate AlkaloidsIBA 06/2009
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2009
1	Minocycline (Cyclops)FDA LinkGeneric 03/2009
1	Sertraline (Zoloft)FDA LinkGeneric 07/2008
1	CholesterolIBA 06/2008
1	dimemorfan (AT 17)IBA 10/2007
1	ORALIT (ORS)IBA 04/2007

Therapy/Procedure

18	Drug Therapy (Chemotherapy) 01/2021 - 05/2006
8	Therapeutics 12/2019 - 07/2005
3	Injections 02/2009 - 04/2005
2	Secondary Prevention 04/2018 - 12/2015
1	Ambulatory Care (Outpatient Care) 01/2021
1	Nebulizers and Vaporizers (Inhaler) 01/2019
1	Liver Transplantation 04/2018
1	Aftercare (After-Treatment) 01/2017
1	Intravenous Administration 04/2013
1	Tobacco Use Cessation Devices 03/2006